AMAG is a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people’s lives. Its products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR, the Company also helps families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.


Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
545 (est)
AMAG Pharmaceuticals was founded in 1981 and is headquartered in Waltham, US
Report incorrect company information

AMAG Pharmaceuticals Office Locations

AMAG Pharmaceuticals has offices in Tucson, San Bruno and Waltham
Waltham, US (HQ)
1100 Winter St
San Bruno, US
1200 Bayhill Dr
Tucson, US
6550 S Bay Colony Dr
Show all (3)
Report incorrect company information

AMAG Pharmaceuticals Financials and Metrics

AMAG Pharmaceuticals Financials

AMAG Pharmaceuticals's revenue was reported to be $609.95 m in FY, 2017
USD

Revenue (FY, 2017)

609.9 m

Gross profit (FY, 2017)

588.1 m

Gross profit margin (FY, 2017), %

96.4%

Net income (FY, 2017)

(199.2 m)

EBIT (FY, 2017)

(293.3 m)

Market capitalization (25-Apr-2018)

698.1 m

Cash (31-Dec-2017)

192.1 m

EV

972.3 m
AMAG Pharmaceuticals's current market capitalization is $698.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

80.9 m124.4 m418.3 m532.1 m609.9 m

Revenue growth, %

54%236%27%

Cost of goods sold

12 m20.3 m10 m20.6 m21.8 m

Gross profit

68.9 m104.1 m408.3 m511.5 m588.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

21.6 m20.8 m24.8 m25.5 m89.5 m123.9 m96.2 m109.3 m127.4 m143.8 m139 b158.4 m

Cost of goods sold

2.5 m2.8 m2.7 m3 m21 m19.7 m3.3 m5.5 m5.2 m5 m5 b5.6 m

Gross profit

19.1 m18 m22.1 m22.5 m68.5 m104.2 m92.9 m103.8 m122.2 m138.8 m134 b152.8 m

Gross profit Margin, %

88%86%89%88%77%84%97%95%96%97%96%96%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

27 m119.3 m228.7 m274.3 m192.1 m

Accounts Receivable

6.8 m38.2 m85.7 m92.4 m103.5 m

Inventories

17.2 m40.6 m40.6 m37.3 m37.4 m

Current Assets

244.4 m274 m606.7 m718.6 m481.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

30.9 m200.9 m202.1 m196.2 m243.8 m89.9 m167.5 m203.4 m251.1 m305.3 m252.9 m260.1 m

Accounts Receivable

8.8 m10.1 m10.6 m10.9 m56.2 m58 m73.7 m82.8 m66.1 m70.1 m85.2 m89.5 m

Inventories

14.7 m20.8 m22 m19.6 m35.9 m34.4 m37.2 m42 m39.6 m38.2 m36.9 m37.5 m

Current Assets

245.6 m421 m424.1 m427 m519.5 m555.5 m655.4 m622.2 m665.6 m736.8 m688.9 m537.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(9.6 m)135.8 m32.8 m(2.5 m)(199.2 m)

Depreciation and Amortization

3.1 m7 m69.1 m99.9 m155.5 m

Inventories

(1 m)(1.4 m)(5.2 m)(2.4 m)(2.3 m)

Accounts Payable

(5.7 m)10.7 m7.9 m49 m16.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(145 k)(7.1 m)(1.5 m)1.5 m12.9 m33.3 m(20.6 m)(7.5 m)(596 k)16.2 m(36.6 b)

Depreciation and Amortization

19.6 m

Inventories

22 m19.6 m35.9 m34.4 m37.2 m(2.2 m)39.6 m38.2 m36.9 m

Accounts Payable

3.5 m1.9 m6 m6.1 m3.7 m(6.6 m)8.7 m4.7 m7.6 m
USDY, 2017

EV/EBIT

-3.3 x

EV/CFO

9 x

EV/FCF

9.8 x

Revenue/Employee

1.1 m

Financial Leverage

2.3 x
Show all financial metrics
Report incorrect company information

AMAG Pharmaceuticals News and Updates

Report incorrect company information